within Pharmacolibrary.Drugs.ATC.B;

model B01AC30
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.7,
    Cl             = 3.3333333333333335e-05,
    adminDuration  = 600,
    adminMass      = 200 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.004,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.001,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>B01AC30</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>This combination includes acetylsalicylic acid (aspirin) and dipyridamole, both of which are antithrombotic agents. It is used to reduce the risk of stroke in patients with a history of transient ischemic attacks or completed thrombotic stroke. The combination is approved and marketed in many countries, often as an extended-release oral formulation.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for healthy adults; no dedicated population PK publication available.</p><h4>References</h4><ol><li><p>Hervey, PS, &amp; Goa, KL (1999). Extended-release dipyridamole/aspirin. <i>Drugs</i> 58(3) 469–477. DOI:<a href=\"https://doi.org/10.2165/00003495-199958030-00007\">10.2165/00003495-199958030-00007</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/10493274/\">https://pubmed.ncbi.nlm.nih.gov/10493274</a></p></li><li><p>MacWalter, RS, &amp; Shirley, CP (2002). A benefit-risk assessment of agents used in the secondary prevention of stroke. <i>Drug safety</i> 25(13) 943–963. DOI:<a href=\"https://doi.org/10.2165/00002018-200225130-00005\">10.2165/00002018-200225130-00005</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12381215/\">https://pubmed.ncbi.nlm.nih.gov/12381215</a></p></li><li><p>Connolly, SJ (2003). Preventing stroke in patients with atrial fibrillation: current treatments and new concepts. <i>American heart journal</i> 145(3) 418–423. DOI:<a href=\"https://doi.org/10.1067/mhj.2003.84\">10.1067/mhj.2003.84</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12660663/\">https://pubmed.ncbi.nlm.nih.gov/12660663</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end B01AC30;
